We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
Read MoreHide Full Article
Shares of Novo Nordisk A/S (NVO - Free Report) have increased 6.4% year to date against the industry’s decline of 0.2%.
Novo Nordisk has a strong presence in the Diabetes care market, with a global market share of 27.9%. Also, the company has a solid footing in the total insulin and modern and new-generation insulin market, with a global market share of 46.4% and 45.2%, respectively. The company has one of the broadest diabetes portfolios in the industry. Solid performance from Tresiba, Victoza, Ozempic, Xultophy and Saxenda boosted sales in 2018.
The company is making efforts to develop new treatments for diabetes, which is its core area of expertise.
In February 2019, the FDA approved Novo Nordisk’s biologics license application (BLA) for Esperoct (turoctocog alfa pegol, N8-GP) to treat haemophilia A in adults and children. The drug is approved for the routine prophylactic to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes plus perioperative management of bleeding in the given patient population. Per the company, due to third-party intellectual property (IP) agreements, it will not be able to launch the drug before 2020 in the United States.
In January 2019, Novo Nordisk initiated a phase I study on LAIsema, the combination of once-weekly insulin LAI287 and once-weekly injectable GLP-1 Ozempic (semaglutide). The study will investigate single-dose pharmacokinetics of LAIsema in a fixed ratio compared with LAI287 and semaglutide given separately to people with type II diabetes.
In December 2018, Novo Nordisk and Staten Biotechnology entered a collaboration and an exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. Per the collaboration agreement, the company will provide research and development funding and support to Staten Biotechnology for developing its lead asset, STT-5058, for the treatment of dyslipidaemia.
Novo Nordisk has decided to submit the application for oral semaglutide in 2019, and notified the FDA that it will request priority review of the filing based on a priority review voucher. The company still expects to file for oral semaglutide for EU approval in the first half of 2019.
In April 2019, Gilead Sciences, Inc. (GILD - Free Report) and Novo Nordisk announced that both the companies intend to collaborate to develop treatments for non-alcoholic steatohepatitis (NASH). The companies will initiate a proof-of-concept study combining Novo Nordisk's semaglutide and Gilead's cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH.
However, Novo Nordisk is going through a rough patch with several drugs in its portfolio losing patent protection. The company is also facing pricing pressure for some of its drugs.
Moreover, the diabetes market is already crowded with a number of drugs. Merck’s (MRK - Free Report) Januvia and Janumet (type II diabetes), Eli Lilly’s (LLY - Free Report) Trulicity (type II diabetes), and Sanofi’s Toujeo (type I and II diabetes) are already approved.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
Shares of Novo Nordisk A/S (NVO - Free Report) have increased 6.4% year to date against the industry’s decline of 0.2%.
Novo Nordisk has a strong presence in the Diabetes care market, with a global market share of 27.9%. Also, the company has a solid footing in the total insulin and modern and new-generation insulin market, with a global market share of 46.4% and 45.2%, respectively. The company has one of the broadest diabetes portfolios in the industry. Solid performance from Tresiba, Victoza, Ozempic, Xultophy and Saxenda boosted sales in 2018.
The company is making efforts to develop new treatments for diabetes, which is its core area of expertise.
In February 2019, the FDA approved Novo Nordisk’s biologics license application (BLA) for Esperoct (turoctocog alfa pegol, N8-GP) to treat haemophilia A in adults and children. The drug is approved for the routine prophylactic to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes plus perioperative management of bleeding in the given patient population. Per the company, due to third-party intellectual property (IP) agreements, it will not be able to launch the drug before 2020 in the United States.
In January 2019, Novo Nordisk initiated a phase I study on LAIsema, the combination of once-weekly insulin LAI287 and once-weekly injectable GLP-1 Ozempic (semaglutide). The study will investigate single-dose pharmacokinetics of LAIsema in a fixed ratio compared with LAI287 and semaglutide given separately to people with type II diabetes.
In December 2018, Novo Nordisk and Staten Biotechnology entered a collaboration and an exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia. Per the collaboration agreement, the company will provide research and development funding and support to Staten Biotechnology for developing its lead asset, STT-5058, for the treatment of dyslipidaemia.
Novo Nordisk has decided to submit the application for oral semaglutide in 2019, and notified the FDA that it will request priority review of the filing based on a priority review voucher. The company still expects to file for oral semaglutide for EU approval in the first half of 2019.
In April 2019, Gilead Sciences, Inc. (GILD - Free Report) and Novo Nordisk announced that both the companies intend to collaborate to develop treatments for non-alcoholic steatohepatitis (NASH). The companies will initiate a proof-of-concept study combining Novo Nordisk's semaglutide and Gilead's cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of patients with NASH.
However, Novo Nordisk is going through a rough patch with several drugs in its portfolio losing patent protection. The company is also facing pricing pressure for some of its drugs.
Moreover, the diabetes market is already crowded with a number of drugs. Merck’s (MRK - Free Report) Januvia and Janumet (type II diabetes), Eli Lilly’s (LLY - Free Report) Trulicity (type II diabetes), and Sanofi’s Toujeo (type I and II diabetes) are already approved.
Novo Nordisk A/S Price
Novo Nordisk A/S Price | Novo Nordisk A/S Quote
Zacks Rank
Novo Nordisk currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>